The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition [2] (multiple letters)

Neuropsychopharmacology

Volumn 26, Issue 5, 2002, Pages 698-699

  Chalon, Stephane ^a   Bieck, Peter R ^a   Goldstein, David J ^a   Detke, Michael J ^a   Bymaster, Franklin P ^a   Potter, William Z ^a   Demitrack, Mark A ^a   Blier, Pierre ^b   Turcotte, Julie ^b   Hébert, Chantal ^b   Debonnel, Guy ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; DULOXETINE; NORADRENALIN; SEROTONIN; SEROTONIN AGONIST; TYRAMINE; VENLAFAXINE;

BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; HORMONE ACTION; HORMONE TRANSPORT; HYPOTHALAMUS; LETTER; METABOLITE; PRESSOR RESPONSE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SENSITIVITY ANALYSIS; TURNOVER TIME; URINE LEVEL;

EID: 0036200457     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00409-2     Document Type: Letter

References (8)

1. F.P Bymaster L.J Dreshfield-Ahmad P.G Threlkeld J.L Shaw L Thompson D.L Nelson S.K Hemrick-Luecke D.T Wong Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors Neuropsychopharmacology 25 2001 871 880
2. Chalon S, Granier L-A, Vandenhende F (2000): Duloxetine clinical evidence of sertoninergic and noradrenergic reuptake blockade. Presented at the American College of Neuropsychopharmacology; December; San Juan, PR.
3. G Debonnel P Blier E St-Andre C Hebert C de Montigny Comparison of the effect of low and high doses of venlafaxine on serotonin and norepinephrine in reuptake processes in patients with major depression and health volunteers Int J Neuropsychopharmacol 1 suppl 1 1998 17
4. Demitrack MA. (2001): Is there room to improve monoamine-based therapies? Presented at the Annual Meeting of the American Psychiatric Association (APA): May 2001; New Orleans, LA.
5. Goldstein DJ, Mallinckrodt C, Lu Y, et al. (2001): Efficacy and safety of duloxetine in the treatment of major depression. Presented at the Annual Meeting of the American Psychiatric Association (APA): May 2001; New Orleans, LA.
6. A.T Harvey R.L Rudolph S.H Preskorn Evidence of the dual mechanisms of action of venlafaxine Arch Gen Psychiatry 57 2000 503 509
7. J.E Turcotte G Debonnel C de Montigny C Hébert P Blier Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects Neuropsychopharmacology 24 2001 511 521
8. Wong DT, Bymaster FP, Dreshfield-Ahmad L. (2000): Effectiveness of duloxetine and venafaxine in producing increases in extracellular levels of serotonin and norepinephrine in brain. Presented at the American College of Neuropsychopharmacology; December, 2000; San Juan, PR.